Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dr. Reddy's Laboratories Limited (DRREDDY.NS)
Hyderabad, IN
Established in 1984 and headquartered in Hyderabad, India, Dr. Reddy's Laboratories Limited functions as a fully integrated global pharmaceutical entity. Its business is structured into several core divisions. The Global Generics segment is responsible for the production and distribution of prescription and over-the-counter finished pharmaceutical products, marketed either under their own brand names or as generic versions therapeutically equivalent to branded formulations, also encompassing biologics. The Pharmaceutical Services and Active Ingredients (PSAI) division manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates, which are fundamental components for finished drugs, alongside offering contract research services and custom production of APIs and steroids. The Proprietary Products segment is dedicated to the research and development of unique and differentiated drug formulations. Furthermore, its "Others" segment focuses on developing treatments for oncology and inflammatory conditions. The company's therapeutic reach spans numerous areas including gastro-intestinal, cardiovascular, anti-diabetic, dermatological, oncology, respiratory, stomatological, urological, and nephrological health. Dr. Reddy's also maintains a strategic collaboration with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists for immuno-oncology and precision oncology applications.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.04% | +4.29% | +8.70% | +4.55% | +7.94% | +5.65% | +10.19% | +49.86% | +27.92% | +122.55% | +6,784.67% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 11 | -1 |
| Hold | 10 | -1 |
| Sell | 6 | 0 |
| Strong Sell | 7 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+3.2% Q1'26: -11.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-24.1% Q1'26: -86.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+5.6% Q1'26: +13.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+13.8% ★ Q1'26: +0.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+9.7% ★ Q1'26: +0.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.1% ★ Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.15× ★ Q1'26: 3.20× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2010 actual |
Mar 2011 actual |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 33 Rev. Ana. 32 EPS Ana. |
Mar 2027 36 Rev. Ana. 34 EPS Ana. |
Mar 2028 36 Rev. Ana. 34 EPS Ana. |
Mar 2029 18 Rev. Ana. 16 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
70.28B
est: 72.97B (-3.7%)
|
74.69B
est: 75.89B (-1.6%)
|
96.74B
est: 95.31B (+1.5%)
|
115.55B
est: 114.94B (+0.5%)
|
147.36B
est: 136.93B (+7.6%)
|
147.36B
est: 148.52B (-0.8%)
|
153.87B
est: 157.97B (-2.6%)
|
139.87B
est: 144.01B (-2.9%)
|
141.86B
est: 144.34B (-1.7%)
|
153.85B
est: 153.46B (+0.3%)
|
174.60B
est: 169.67B (+2.9%)
|
189.72B
est: 191.30B (-0.8%)
|
214.39B
est: 212.14B (+1.1%)
|
245.88B
est: 241.90B (+1.6%)
|
279.16B
est: 276.77B (+0.9%)
|
325.54B
est: 323.68B (+0.6%)
|
343.38B
338.11B – 359.88B
+6.1% YoY
|
358.20B
335.44B – 391.92B
+4.3% YoY
|
395.70B
365.83B – 450.87B
+10.5% YoY
|
433.88B
403.60B – 485.03B
+9.6% YoY
|
| EBITDA |
6.59B
est: -3.10B (+312.2%)
|
16.88B
est: 10.71B (+57.6%)
|
24.69B
est: 20.81B (+18.7%)
|
25.82B
est: 28.29B (-8.7%)
|
35.16B
est: 33.81B (+4.0%)
|
35.16B
est: 36.29B (-3.1%)
|
40.18B
est: 40.95B (-1.9%)
|
24.55B
est: 32.49B (-24.4%)
|
23.74B
est: 26.68B (-11.0%)
|
31.87B
est: 25.68B (+24.1%)
|
41.79B
est: 38.88B (+7.5%)
|
45.71B
est: 36.58B (+25.0%)
|
47.74B
est: 40.85B (+16.9%)
|
66.05B
est: 44.67B (+47.9%)
|
79.29B
est: 47.77B (+66.0%)
|
88.84B
est: 54.67B (+62.5%)
|
85.70B
84.38B – 89.82B
+56.7% YoY
|
89.40B
83.72B – 97.81B
+4.3% YoY
|
98.75B
91.30B – 112.52B
+10.5% YoY
|
108.28B
100.72B – 121.05B
+9.6% YoY
|
| EBIT |
2.43B
est: -6.73B (+136.0%)
|
12.68B
est: 5.73B (+121.4%)
|
19.53B
est: 13.58B (+43.8%)
|
20.27B
est: 21.49B (-5.7%)
|
27.06B
est: 23.33B (+16.0%)
|
27.06B
est: 28.56B (-5.3%)
|
29.93B
est: 29.43B (+1.7%)
|
13.27B
est: 27.77B (-52.2%)
|
12.03B
est: 14.28B (-15.8%)
|
19.68B
est: 13.61B (+44.6%)
|
29.31B
est: 22.18B (+32.1%)
|
32.91B
est: 14.77B (+122.9%)
|
35.92B
est: 16.49B (+117.8%)
|
53.42B
est: 18.03B (+196.2%)
|
65.59B
est: 19.28B (+240.2%)
|
73.03B
est: 63.02B (+15.9%)
|
67.46B
66.43B – 70.70B
+7.0% YoY
|
70.37B
65.90B – 77.00B
+4.3% YoY
|
77.74B
71.87B – 88.58B
+10.5% YoY
|
85.24B
79.29B – 95.29B
+9.6% YoY
|
| Net Income |
1.07B
est: -10.31B (+110.4%)
|
11.04B
est: 3.66B (+202.0%)
|
14.26B
est: 12.54B (+13.7%)
|
16.78B
est: 15.69B (+6.9%)
|
22.18B
est: 18.70B (+18.6%)
|
22.18B
est: 21.54B (+3.0%)
|
20.01B
est: 25.02B (-20.0%)
|
12.04B
est: 19.27B (-37.5%)
|
9.81B
est: 12.70B (-22.8%)
|
18.80B
est: 10.12B (+85.8%)
|
19.50B
est: 21.17B (-7.9%)
|
17.24B
est: 22.77B (-24.3%)
|
23.57B
est: 25.42B (-7.3%)
|
45.07B
est: 27.80B (+62.1%)
|
55.68B
est: 29.73B (+87.3%)
|
56.54B
est: 57.03B (-0.9%)
|
49.80B
45.78B – 55.53B
-12.7% YoY
|
42.89B
33.58B – 55.75B
-13.9% YoY
|
52.75B
40.74B – 66.64B
+23.0% YoY
|
63.02B
57.31B – 72.68B
+19.5% YoY
|
| SGA |
22.51B
est: 12.35B (+82.3%)
|
23.69B
est: 13.51B (+75.3%)
|
28.87B
est: 18.26B (+58.1%)
|
33.58B
est: 21.39B (+57.0%)
|
42.08B
est: 26.12B (+61.1%)
|
42.08B
est: 55.95B (-24.8%)
|
45.64B
est: 62.73B (-27.2%)
|
46.30B
est: 48.87B (-5.3%)
|
46.86B
est: 55.09B (-14.9%)
|
48.68B
est: 60.58B (-19.6%)
|
50.13B
est: 63.40B (-20.9%)
|
54.65B
est: 66.08B (-17.3%)
|
62.08B
est: 73.80B (-15.9%)
|
68.03B
est: 80.71B (-15.7%)
|
76.92B
est: 86.30B (-10.9%)
|
92.85B
est: 92.70B (+0.2%)
|
99.22B
97.70B – 103.99B
+7.0% YoY
|
103.51B
96.93B – 113.25B
+4.3% YoY
|
114.34B
105.71B – 130.29B
+10.5% YoY
|
125.38B
116.62B – 140.16B
+9.6% YoY
|
| EPS |
6.33
est: 53.06 (-88.1%)
|
65.28
est: 64.69 (+0.9%)
|
84.16
est: 85.04 (-1.0%)
|
98.82
est: 94.81 (+4.2%)
|
26.04
est: 129.61 (-79.9%)
|
26.04
est: 26.61 (-2.1%)
|
23.47
est: 29.57 (-20.6%)
|
14.45
est: 16.23 (-11.0%)
|
11.83
est: 13.23 (-10.6%)
|
22.66
est: 21.48 (+5.5%)
|
23.53
est: 25.22 (-6.7%)
|
20.79
est: 30.55 (-32.0%)
|
28.42
est: 34.35 (-17.3%)
|
54.29
est: 47.16 (+15.1%)
|
66.93
est: 64.05 (+4.5%)
|
67.88
est: 68.01 (-0.2%)
|
59.76
54.94 – 66.64
-12.1% YoY
|
51.47
40.29 – 66.89
-13.9% YoY
|
63.30
48.89 – 79.97
+23.0% YoY
|
75.63
68.77 – 87.22
+19.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X India Nifty 50 ETF NDIA.AX | 0.69% | 866.6K | 0.69% |
| 2 | Vanguard Global Minimum Volatility ETF VVO.TO | 0.63% | 186.3K | 0.36% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.07% | 2.23M | 0.26% |
| 4 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.01% | 177.1K | 0.22% |
| 5 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 533.6K | 0.22% |
| 6 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 286.8K | 0.22% |
| 7 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 126.4K | 0.22% |
| 8 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 14.6K | 0.22% |
| 9 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 4.8K | 0.31% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 2.3K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gunupati Venkateswara Prasad | Co-Chairman, MD & Member of Management Council | 188M | male |
| Kallam Satish Reddy | Chairman of the Board & Member of the Management Council | 118M | male |
| Bhethanabottla S. Phanimitra | Chief Digital and Information Officer & Member of the Management Council | — | male |
| Deepak Sapra | Global Head of Pharmaceutical Services and Active Ingredients & Member of Management Council | — | male |
| Erez Israeli | Chief Executive Officer & Member of the Management Council | — | male |
| Krishna K. Venkatesh B.Pharma | Global Head of IPDO, Integrated Product Development & Member of the Management Council | — | male |
| Mannam Venkatanarasimham | Chief Financial Officer & Member of the Management Council | — | male |
| Milan Kalawadia | Chief Executive Officer of North America & Member of Management Council | — | male |
| Motupalli Venkata Ramana | CEO of Global Generics & Member of Management Council | — | male |
| Patrick Aghanian | Head of Consumer Health Organization & Member of Management Council | — | male |
| Sanjay Sharma | Executive VP, COO & Member of Management Council | — | male |
| Saunak Savla | Investor Relations Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DRREDDY.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
